Two thirds of breast cancers express estrogen receptors (ER). ER alpha (ERa) mediates breast cancer cell proliferation, and expression of ERa is the standard choice to indicate adjuvant endocrine therapy. ERbeta (ERb) inhibits growth in vitro; its effects in vivo have been incompletely investigated and its role in breast cancer and potential as alternative target in endocrine therapy needs further study. In this work, mammary epithelial (EpH4 and HC11) and breast cancer (MC4-L2) cells with endogenous ERa and ERb expression and T47-D human breast cancer cells with recombinant ERb (T47-DERb) were used to explore effects exerted in vitro and in vivo by the ERb agonists 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY). In vivo, ERb agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ERa agonist 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17b-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features. In vitro, in MC4-L2, EpH4 or HC11 cells incubated under basal conditions, ERb agonists induced apoptosis measured as upregulation of p53 and apoptosis-inducible factor protein levels and increased caspase 3 activity, whereas PPT and E2 stimulated proliferation. However, when extracellular signal-regulated kinase 1 and 2 (ERK ½) were activated by co-incubation with basement membrane extract or epidermal growth factor, induction of apoptosis by ERb agonists was repressed and DPN induced proliferation in a similar way as E2 or PPT. In a context of active ERK ½, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) signalling was necessary to allow proliferation stimulated by ER agonists. Inhibition of MEK ½ with UO126 completely restored ERb growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERb-induced proliferation. These results show that the cellular context modulates ERb growth-inhibitory effects and should be taken into consideration upon assessment of ERb as target for endocrine treatment.
INTRODUCTION
Estrogen receptors (ER) alpha (ERa) and beta (ERb) are ligandactivated transcription factors with high sequence and structural homology, and similar affinity for the endogenous estrogen 17b-estradiol (E2). ERa and ERb have overlapping DNA-binding sites, and also regions selectively bound by either receptor. 1, 2 Therefore, each receptor can activate different gene expression programs and biological responses.
ERa is essential for mammary epithelial cell (MEC) proliferation and ductal development; 3 while at this stage, ERb loss has no effect. Instead, lactating mammary glands from ERb À / À mice show high Ki67, reduced integrin a2 and E-cadherin staining. 4 In vitro, ERa ligand activation stimulates HC11 MEC proliferation, whereas ERb activation induces apoptosis. 5 Ligand activation of ERb increases E-cadherin protein levels 6, 7 and attenuates b-catenin signalling; 7 while ERb knockdown leads to E-cadherin degradation, b-catenin activation and impaired formation of acinar colonies. 6 Thus, ERb counteracts ERa growth stimulatory signals and maintains MEC homoeostasis.
ERa stimulates breast cancer growth and it is the standard to indicate adjuvant endocrine therapy. 8 As there is a lack of breast cancer cell lines with endogenous ERb expression, recombinant ERb is overexpressed, which often inhibits ERa-induced transcription. 9, 10 ERb re-expression inhibits proliferation, 11, 12 migration, 11, 13 erbB2/erbB3/AKT (RAC-alpha serine/threonineprotein kinase) signalling 14 and sensitizes cells to tamoxifen and its metabolites. 14, 15 Therefore, ERb expression could be therapeutically exploited with selective agonists.
14 However, effects mediated by recombinant ERb are mostly ligand independent and may not reflect cellular response in vivo.
The study of ERb in human breast cancer has been stalled by the lack of reliable antibodies, limited amount of cell lines expressing ERb and the number of splice variants expressed in different cell types and organisms. 16 Epidemiological studies have shown that most ER-positive breast cancers express ERb, although to a lower extent as compared with normal mammary epithelium. 17, 18 In breast tumours, ERb expression is associated with ERa and progesterone receptor co-expression, 19 and also found in ½ of ERa-negative cancers that respond to endocrine therapy. 18 However, ERb use as prognostic marker is still under debate; although one study found ERb to be an independent predictor of disease-free survival, 20 another one found ERb expression uninformative. 21 Further, in ERa-negative cancers, ERb expression is associated with the proliferation marker Ki67, 22, 23 which does not correlate with the proposed tumoursuppressor role of ERb.
Receptor tyrosine kinases and their downstream effectors target ERs 24 and enhance ER ligand-dependent and -independent transactivation, modulate ER affinity for ligands, DNA and transcriptional co-activators. 25 As ERb may be targeted by receptor tyrosine kinase signalling, the effects exerted by ERb agonists should be addressed in more complex systems, ideally in vivo. In a mammary cancer model, with endogenous ERa and ERb expression, in which estrogens induce inhibition of tumour growth, the ERb-selective agonist 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) exerted a similar inhibitory effect as the ERa agonist 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or E2. This indicates that in vivo, ERa and ERb may trigger similar responses. Interestingly, after a few days, DPN-treated tumours began to grow, 26 suggesting that ERb-mediated effects may vary depending on the tumour growth stage.
The aim of this study was to analyse effects mediated by endogenous ERb in mammary epithelial (MECs) and breast cancer cells in vitro and in vivo. Administration of ERb agonists in vivo stimulated mammary tumour growth and ductal hyperplasia, whereas in vitro, ERb agonists induced apoptosis. p-ERK levels were higher in breast cancer cells grown in vivo compared with in vitro, and activation of MAPK signalling by basement membrane (BM) or epidermal growth factor (EGF) in vitro blocked growth inhibition induced by ERb agonists. Interestingly, in a context of active MAPK, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signalling was necessary to allow proliferation induced by ERb. Taken together, these results indicate that the cellular context can modulate ERb-mediated effects.
RESULTS

Regulation of mammary epithelial and breast cancer cell growth by ERa and ERb
Effects exerted on proliferation and apoptosis by the ERb agonists DPN or 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY), E2 or the ERa agonist PPT in MC4-L2 breast cancer cells or MECs were evaluated.
Proliferation, assessed by bromodeoxyuridine (BrdU) incorporation, increased by 25-50% following incubation with E2 or PPT ( Figure 1a ) and correlated with ERa expression levels (Supplementary Figures 1A and B) . On the contrary, DPN or WAY did not significantly affect BrdU incorporation in any of the cell lines tested (Figure 1a and Supplementary Figure 3A , respectively). Co-treatment with 4OH-tamoxifen (4OH-T) completely prevented E2 and PPT stimulation of proliferation (Supplementary Figure 3B) , which indicates that proliferation signals occur through the nuclear receptor pathway. Whether ERa alone or ERa/ERb heterodimers are involved remains to be established.
Apoptosis was evaluated as caspase 3 (Casp 3) activity (Figure 1b ). ERb activation with DPN (ERb-DPN) increased Casp 3 activity in all cell lines; although E2 exerted no significant effect on MC4-L2 and HC11 cells but also induced Casp 3 activity in EpH4 cells. Activation of Casp 3 by DPN correlated with upregulation of p53 protein (Figure 1c) , which was also confirmed in cells treated with WAY (Supplementary Figure 3C) . In addition, E2 and DPN upregulated apoptosis-inducible factor (Aif) in EpH4 and HC11 cells (Figure 1d ).
ERb-induced apoptosis associated to p53 upregulation has been shown in HC11 cells. 27 HC11 and MC4-L2 cells have mutated p53. 28, 29 However, transcriptionally inactive p53 mutants can induce apoptosis 30 and p53 also induces apoptosis in the absence of transcription, 31 which may be the case in these cells.
In HC11 cells, PPT increased and DPN reduced cell number, but no net effect was observed with E2. 5 A similar picture was observed in EpH4 cells, while in MC4-L2 cells, E2 also increased cell number (Figure 1e ). These effects were reverted by co-treatment with 4OH-T (Supplementary Figure 3D) . Therefore, E2, which can activate ERa and ERb, preferably induced ERa-mediated proliferation in a larger proportion of MC4-L2 breast cancer cells (with higher ERa expression levels) as compared with MECs, in which E2, similarly to ERb agonists (DPN or WAY) also induced apoptosis through p53 and Casp 3 (EpH4) or Aif (EpH4 and HC11), which resulted in no differences in cell number. It is possible that, as shown previously for HC11 cells, 5 in EpH4 cells, the dual effect exerted by E2 depends on the varying ERa/ERb ratios throughout the cells.
Treatment of mouse mammary tumours and mammary glands with ERa or ERb agonists stimulates growth MC4-L2 tumour growth is stimulated by E2 28 and inhibited by letrozole and raloxifene. 32 To study ERb-DPN effect on tumour growth, mice bearing MC4-L2 tumours were treated with DPN for 17 days. Tumour growth was significantly stimulated by DPN in a similar way as observed in E2-or PPT-treated groups (Figure 2a ), and correlated with upregulation of cyclin D1 protein ( Figure 2b ) and higher number of mitotic features than the control group (Figure 2c and d, arrows), indicating that DPN induced cell proliferation. In addition, smaller number of apoptotic bodies were observed in DPN-treated group (Figure 2c and d, arrowheads). As DPN exerted similar effects as the ERa agonist PPT, selectivity of DPN treatment in vivo was confirmed by quantification of uterine lactoferrin and complement C3 mRNA, which were only upregulated by E2 and PPT 33 (that is, ligand-activated ERa; Supplementary Figure 4A ). Therefore, in vivo, a dose of ERb agonist, which does not activate ERa, induced cell proliferation and inhibited apoptosis.
Effects exerted by ERb agonists DPN and WAY were evaluated in the fourth contralateral mammary gland following 5-or 17-day treatment. Already after 5 days, DPN and to a lower extent WAY or E2 induced ductal growth and lateral branching ( Figure 3 , left panel) as well as proliferation measured as Ki67 staining (Supplementary Figure 4B) . Actively proliferating terminal end buds (arrowheads) were found and areas of ductal hyperplasia were observed ( Figure 3 , right panel). These results indicate that, as shown in MC4-L2 tumours, activation of ERb in vivo induced proliferation of the mammary epithelium.
Notably, results obtained with ERb agonists in vivo were in clear contrast to those observed in vitro.
BM reverts ERb growth-inhibitory effects
The extracellular matrix influences signalling by ovarian hormones 34 and could modulate effects exerted by ERb agonists in vitro and in vivo. To analyse the contribution of the BM to ERb signalling, MC4-L2 cells were grown with 5% BM (Matrigel). Under these conditions, MAPK signalling was stimulated (that is, upregulation of extracellular signal-regulated kinase 1 and 2 (ERK ½) phosphorylated in thr202/tyr204; p-ERK ½) and downregulated by co-incubation with BM and the MEK ½ inhibitor UO126 (Figure 4a Figures 1a and 4a) . Proliferation induced by any ER agonist used was completely reverted by co-incubation with 4OH-T or UO126 (Figure 4b and Supplementary Figure 5A) . Levels of p53 protein, which in cells grown without BM ( À BM) were upregulated by ERb agonists (Figure 1b and Supplementary Figure 3C ), were reduced when cells were grown with BM ( þ BM; Figure 4c ). Co-incubation of MC4-L2 cells þ BM reduced DPN effects on Casp 3 activity to control levels, whereas UO126 completely restored Casp 3 activity as well as upregulation of p53 induced by ERb-DPN (Figure 4d ). In cells þ BM, E2 exerted a slight inhibition of Casp 3 activity and no effect on p53 protein levels; yet, E2 co-incubation with UO126 (complete downregulation of ERK ½ levels) increased Casp 3 activity and also upregulated p53 protein (Figure 4d ). Therefore, in the absence of active ERK ½, E2 may preferentially activate ERb and induce apoptosis. Alternatively, active ERa (that is, phosphorylated in AF-1 and AF-2) may be necessary to inhibit ERb-E2-induced apoptosis by formation of ERa/ERb heterodimers and transactivation of proliferation genes.
The decrease in MC4-L2 cell number induced by ERb-DPN in cells -BM ( Figure 1e ) was not observed in cells cultured þ BM; however, co-culture with UO126 completely restored ERb inhibition of cell number (Figure 4e ). These results show that activation of MAPK signalling by BM fully blocks growth-inhibitory effects exerted by ERb agonists. These results indicate that, as observed in MECs, activation of ERK ½ signalling stimulates proliferation and inhibits apoptosis induced by ERb agonists.
In T47-DERb cells, ERb expression activates transcription programs associated with inhibition of cell cycle and apoptosis. 12, 37 Therefore, T47-DERb cells were used to further study if active ERK ½ could block growth inhibition induced by recombinant ERb in human breast cancer cells.
When ERb expression remained turned off ( À ERb), cell number was not affected by DPN (Figure 6a ), which is consistent with the fact that T47-D cells have no detectable ERb protein. Following ERb induction ( þ ERb), cell number was reduced to 50% in a ligand-independent manner. However, in þ ERb cells, incubation þ EGF partially increased cell number, and co-incubation with DPN exerted an even greater increase (Figure 6a ). ERb effects in þ EGF medium were reverted to -EGF levels by co-incubation with UO126.
Casp 3 activity was increased in T47-DERb cells expressing ERb (not shown) and was further increased by the addition of DPN (Figure 6c) , whereas co-incubation of ERb-expressing cells þ EGF partially reduced Aif and increased PCNA. In addition, Aif levels were further downregulated by DPN, suggesting that in cells þ EGF, ligand-dependent stimulation of growth may be due to inhibition of apoptosis pathways by ERb-DPN.
Thus, ERK ½ signalling modulates ligand-independent effects mediated by recombinant ERb at the proliferation level and also blocks ligand-dependent and -independent apoptosis induced by ERb.
Inhibition of PI3K/AKT signalling prevents stimulation of proliferation by ERb HC11 MECs require addition of insulin for optimal growth. 38, 39 As our initial interest was to explore the effect of ERb agonists in other cell lines, treatment of cells was always carried out in insulincontaining medium that can activate PI3K and MAPK signalling. As MAPK/ERK ½ activation inhibited effects exerted by ERb agonists, it was next investigated if insulin, through activation of PI3K/AKT signalling, could also modulate ERb activity. In MC4-L2 and EpH4 cells, insulin addition activated PI3K/AKT signalling, but did not affect p-ERK ½ levels. Co-incubation with BM further increased p-AKT levels; however, in MECs, co-incubation with EGF and insulin did not (Figures 7a and 8a) . Upregulation of p-ERK ½ in þ BM or þ EGF cells was verified. The PI3K inhibitor LY294002 blocked p-AKT upregulation by insulin, and in addition, partially downregulated p-ERK ½ levels in cells grown þ BM or þ EGF, indicative of cross talk between PI3K and MAPK pathway (Figures 7a and 8a) . No effect of Ly294002 was observed on p-ERK ½ levels in cells -BM (Figure 7a ) or -EGF (not shown).
Proliferation was not affected by insulin treatment in MC4-L2 breast cancer cells (Figure 7b ). However, in EpH4 cells, insulin addition was necessary for E2-induced proliferation and to prevent ERb-DPN inhibition of proliferation (Figure 8b ). In both cell lines, co-incubation with LY294002 reverted the effects of insulin and completely prevented proliferation induced by E2. In cells þ BM or þ EGF, LY294002 also inhibited proliferation stimulated by E2 or ERb-DPN. These results suggest that although MECs are more dependent on insulin signalling, both MECs and breast cancer cells require active ERK ½ and AKT to allow stimulation of proliferation by ERs.
Insulin/PI3K signalling did not affect Casp 3 activity induced by ERb-DPN (Figures 7c and 8c) ; however, it was necessary to inhibit E2 induction of Casp 3 in MC4-L2 cells (Figure 7c ), which correlated with p53 upregulation under these incubation conditions (Supplementary Figure 5B) . In cells grown þ BM, inhibition of PI3K/AKT did not restore induction of Casp 3 or p53 upregulation by ERb-DPN and only slightly increased Casp 3 activity induced by E2 (Figure 7c and Supplementary Figure 5B) ; possibly through downregulation of p-ERK ½ levels and not of pAKT. In EpH4 cells, inhibition of PI3K/AKT pathway showed a similar effect on induction of Casp 3 by ERb-DPN (Figure 8c) . Consequently, co-treatment with LY294002 þ BM or þ EGF only prevented ERb-DPN increase in cell number effects, through inhibition of proliferation but did not revert effects to achieve growth inhibition (Figure 7d and Figure 8d , respectively).
BM induces phosphorylation of endogenous ERb MAPK and PI3K signalling enhance ERb phosphorylation 40 thereby inducing ligand-dependent and -independent ER transcriptional activation. 24 ER transcriptional regulation may be accomplished through direct phosphorylation or through phosphorylation of co-activators associated to the transcriptional machinery. To test if BM induced ER phosphorylation, endogenous ERb was immunoprecipitated with 14C8 antibody. BM induced ERb serine phosphorylation (p-Ser), while inhibition of MAPK pathway but not of PI3K/AKT pathway reduced p-Ser levels (Supplementary Figure 7) . These results provide evidence that MAPK pathway targets endogenous ERb for phosphorylation.
DISCUSSION
There is little correlation between the tumour-suppressor role attributed to ERb and epidemiologic observations. In vitro studies have used mostly recombinant ERb, an experimental setting in which growth-inhibitory effects are generally, although not always, observed. [12] [13] [14] These studies have introduced the idea that stimulation of ERb signalling may protect from breast cancer (that is, high phytoestrogen consumption such as genistein) 41 or could be an alternative choice of therapy for endocrine-resistant tumours. 14, 42 In this work, it is proposed that ERb-mediated effects are modulated by MAPK/ERK ½ and PI3K/AKT activation. It has long been known that MAPK and PI3K signalling cross talk with ER and, as such, affect ligand-dependent and -independent transcriptional activation of ERa or recombinant ERb. 24 The novelty of the study presented herein relies in the use of cell lines with endogenous ERa and ERb expression, the comparison of effects to recombinant ERb and the establishment of the concept that the cellular context determines the response to ERb agonists.
Main findings from this work can be summarized as follows: ERb ligand activation increased caspase-dependent (p53 and Casp 3 activity) and -independent (Aif) apoptosis, whereas ERa ligand activation with E2 or PPT required ERK ½ and PI3K activity to stimulate proliferation. Activation of MAPK/ERK ½ by extracellular factors did not enhance ERa-mediated proliferation but reduced ERb effects on p53, Aif and Casp 3 activity to control levels, as well as allowed ERb-induced proliferation; such growth stimulatory effects were completely blocked by inhibition of ERK ½ activation with UO126. Additionally, ERK ½ inactivation allowed E2 to preferentially stimulate apoptosis. On the other hand, in a context of active ERK ½, PI3K/AKT signalling was necessary to allow ERinduced proliferation. Taken together, these findings provide a mechanism that should be explored in human breast cancers, particularly aggressive phenotypes such as HER2 and triplenegative or ERa-negative tumours, which express ERb in a substantial proportion and also present high mitotic index. 43 An association between MAPK activation, ligand-independent upregulation of ERb p-Ser levels and inhibition of apoptosis was found. Future studies are needed to establish if ERb is a direct target of MAPK signalling, whether ligand-independent p-Ser increase affects ERb affinity for agonists and if it favours formation of homodimers or ERb/ERa heterodimers. Phosphorylation influences ERa transcriptional activity, affinity for ligands and DNA. 25 Therefore, the complexity of E2 signalling relies on ERa/ERb ratios 5 and signalling pathways, which phosphorylate ERs and/or their transcriptional co-factors. As such, analysis of the effects exerted by ERb agonists must consider the fact that complex settings with differential ER posttranslational modifications will most certainly influence ERb activity.
In the mouse, an ERb variant that contains an in-frame 18 amino-acid insertion in the ligand-binding domain (ERb2) has been described. ERb2 does not bind ligand but may function as transcriptional repressor of full-length ERb. 44 Mouse cell lines used in this study express low levels of ERb2 compared with full-length ERb; therefore, it is likely that most effects mediated by ERb agonists are not affected by ERb2. However, the possibility that MAPK or PI3K signalling also target these isoform and in some way modulate ERb2 interaction with ligand-binding ER forms remains open.
Few studies have analysed the effect of ERb agonists in the mammary gland or mammary tumours. In vivo administration of genistein increased the number of mammary terminal end buds and ductal branching in a similar way as diethylbestrol. 45 As genistein is a weak selective ERb agonist, it can be argued that in this experimental setting it can also activate ERa. However, in our work, the ERb-selective agonists DPN and WAY, in concentrations that did not activate ERa-mediated transcription, also increased the number of terminal end buds, lateral branching and Ki67 staining. ERb À / À glands develop normally; 46 yet, epithelial ERa is essential for ductal proliferation and subsequent morphogenetic steps like side branching and alveologenesis. 3 Therefore, it is likely that ductal proliferation observed in DPN-or WAY-treated mice is mediated by ERa/ERb heterodimers. However, full differentiation of the mammary epithelium during lactation is compromised by loss of ERb, 4 an effect which at some stage relies on ERb inhibition of E-cadherin internalization and degradation induced by ERa. 6 ERb overexpression in T-47D cells reduces migration through induction of integrin a1/b1; migration is not restored upon stimulation with EGF. 13 These results suggest selective regulation of ERb activity by MAPK and PI3K pathway.
The ERb agonist DPN also induced proliferation and reduced apoptosis of MC4-L2 mouse mammary tumours, which suggests that to understand the role of ERb in breast cancer, physiological regulation of ERa/ERb ratios, ER phosphorylation status and MAPK/PI3K activation levels should be taken into consideration. In this context, ERb phosphorylation on serine 105 was recently identified as a good prognostic factor in response to tamoxifen. 47 In summary, the cellular context modulates ERb-induced apoptosis and proliferation. From the clinical point of view, a benefit from ERb growth-inhibitory effects may still be possible by combining the use of ERb agonists and receptor tyrosine kinase inhibitors or function-blocking antibodies. Yet, results presented in this work suggest that ERb phosphorylation status and kinase signalling should be taken into account when analysing ERb potential as prognostic factor and therapeutic target. Trizol, Superscript III and SYBR-Green Mastermix were from Invitrogen (Paisley, UK). RNA purification columns and on column DNase I were from Qiagen (Hilden, Germany). Immunoblot reagents were from BioRad (Hercules, CA, USA). Primary antibodies: anti-ERa (sc-542), anti-cyclin D1 (sc-753), anti-phospho p42/p42 thr202/tyr204 (sc-16982-R); anti-p53 (sc-99), anti-Aif (sc-13116) and anti-b-actin (sc-130656) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-pan ERK (#610123), antiphospho AKT ser473 (#550747) and anti-total AKT (#610860) from BD Biosciences; anti-ERK ½ (#9107) and anti-phospho AKT ser473 (#4060) from Cell Signaling (Beverly, MA, USA); anti-phospho serine (#05-1000) from Millipore (Billerica, MA, USA). Anti-ERb antibodies were from Abcam (Cambridge, UK). Specificity of mouse anti-ERb 14C8 antibody has been previously shown with siRNAs to ERb. 6 Specificity of anti-chicken 14021 antibody has been previously shown using recombinant ERb. 13 Rabbit antiERb2 and chicken anti-ERb (503) antibody were a kind gift from Dr Margaret Warner. Anti-ERb2 antibody was generated by immunizing with a peptide corresponding to the 18 amino-acid insertion found in ERb2, whereas 503 antibody was generated by immunizing with full-length ERb1 protein.
MATERIALS AND METHODS
Cell culture HC11 and EpH4 are mouse MECs. 48, 49 MC4-L2 cells were obtained from a highly metastatic mouse mammary adenocarcinoma. 28 All cell lines express ERa and ERb mRNA and protein (Supplementary Information, Supplementary Figures 1A and B, respectively) . MC4-L2 tumours express ERa, PR, erbB2 28 and ERb (Supplementary Figure 1C) ; MC4-L2 cells do not respond to EGF (unpublished). T47-DERb cells were obtained by stable expression of ERb in human T47-D breast cancer cells (ERa þ , ERb À ) using a tet-off system. 12, 13 In this system, doxycyclin withdrawal induces ERb expression (Supplementary Figure 1D) . In the rodent, an 18 amino-acid insertion in the ligand-binding domain of ERb originates a splice variant (ERb2). As ERb2 can also be detected by the antibodies used herein, expression of ERb2 was also analysed. In our hands, this antibody works for immunoprecipitation or immunofluorescence. ERb2 was detected in all cell lines in very low amounts (HC11 not shown, Supplementary Figure 1E) . In HC11 cells, ERb2 was detected in 10% cells as compared with ERb.
HC11 cells were grown in RPMI 1640 with 5 mg insulin, 10 ng/ml EGF, 5 mg/l gentamicin and 10% FBS. EpH4 and MC4-L2 cells were grown in DMEM/F12 with 5 mg/l gentamicin and 10% FBS. T47-DERb cells were grown in RPMI 1640 with 10% FBS, 1% penicillin-streptomycin and 10 ng/ml doxycyclin. Cells were preincubated in serum-free RPMI 1640 (2 g/l glucose) or DMEM (4.5 g/l glucose) phenol red-free medium with 5 mg insulin; additionally, ERb expression was induced in T47-DERb cells. Following 24 h, cells were treated with 1-10 nM E2, PPT DPN or WAY or same volume of solvent (EtOH) in preincubation medium plus 1% steroid charcoal striped FBS with or without 10 ng/ml EGF or 5% BM. Preincubation in serum-free medium was used to synchronize cells in S phase of cell cycle prior initiation of treatments; yet, similar results were obtained in unsynchronized cells (Supplementary Figure 2) .
Cell counting
Twenty thousand cells were seeded in 24-well plates and grown as described above. Following 3-day ligand treatment, cells were detached and duplicates of each well counted in a Neubauer chamber. Cell number variation was calculated by normalizing all values to the agonist untreated control. Results are presented as mean±s.e.m. of at least three independent cultures, each carried out in sextuplicates.
Proliferation assay
Two thousand cells were seeded in 96-well plates, grown as described above. Following 48 h ligand treatment, medium was refreshed and 10 mM BrdU were added. Twenty-four hour later, cells were fixed and BrdU incorporation quantified with the Colorimetric Cell proliferation ELISA kit (Roche, Mannheim, Germany). Experiments were carried out in quadruplicates and repeated with three independent cultures. Relative variation was calculated by normalizing all values to the agonist untreated control. Results are presented as mean ± s.d. of a representative experiment of at least three.
Caspase 3 assay
Apoptosis was evaluated with the colorimetric Caspase 3 assay kit (CASP-3-C, Sigma). Cells were grown as described above, in 10 cm dishes until 60% confluence. Following 24 h treatment, cells were lysed (2.5 mM HEPES, pH 7.4, 2.5 mM CHAPS and 2.5 mM dithiothreitol) and centrifuged at 14 000 g, 10 min, 4 1C. Casp 3 activity was measured in duplicates with Ac-DEVD-pNA substrate. Absorbance units from a parallel reaction in the presence of Casp 3 inhibitor (Ac-DEVD-CHO) were subtracted. Results were normalized to protein concentration in each lysate. Relative Casp 3 activity was calculated by normalizing all values to the agonist untreated control. Unless otherwise stated, results are presented as mean ± s.e.m. of at least three independent experiments.
Animal experiments
Mice were fed ad libitum and kept under a 12-h light-dark cycle. Twomonth-old virgin BALB/c mice were injected in the left inguinal side with 1 Â 10 6 MC4-L2 cells in PBS. Tumour size was measured every 2 days with a calliper (width Â length). Treatment started when tumours reached 0.5 cm 2 (B26 days after injection). Treatment (0.5 mg E2, 150 mg PPT and 50 mg DPN per animal) was administered in daily s.c. injections. Working solutions where prepared in PBS from stocks prepared in EtOH-DMSO (50:50) as shown previously. 33 Four animals were included in each group and the experiment was repeated twice. Following 17-day treatment (when the maximum tumour size allowed by the ethical committee was reached), animals were killed, and tumours, uterus and the contralateral mammary gland were excised. In addition, healthy animals were also treated with same concentrations of E2, PPT or DPN as tumours (daily, s.c.) or WAY (30 mg/kg). Tumours and uteri were either frozen in liquid nitrogen or fixed in 10% formalin for immunohistological studies. Mammary glands, from tumour bearing or from healthy animals were processed for whole mount or fixed in 10% formalin. All animal experimentation was conducted in accordance with standards of humane animal care as outlined by the Stockholm South Ethical Committee of the Swedish National Board for Laboratory Animals. Ethical permit no. S194-07.
Whole mount and histological analysis
The fourth mammary gland was excised, spread on a glass slide and immediately fixed in Carnoýs fixative for 2 h. Samples were gradually rehydrated through a series of decreasing % EtOH and stained in carmine alum over night. Mammary glands were dehydrated, cleared in xylene and mounted with DPX. Quantification of mitosis and apoptosis was carried out by counting typical features on eight high power fields per tumour sample stained with hematoxylin and eosin.
RNA extraction and real-time PCR RNA was extracted with TRIzol, purified using spin columns. cDNA was synthesized with Superscript III kit and random hexamers using 1 mg DNase-I-treated and purified RNA. Real-time PCR was performed with SYBR-Green Mastermix in an ABI PRISM 7500 (Applied Biosystems, Carlsbad, CA, USA). Conditions were: 95 1C for 10 min, followed by 40 cycles at 95 1C for 15 s and 60 1C for 40 s. All runs were performed in triplicate and specific amplification was checked with melting curve analysis. Complement C3, Gapdh and lactoferrin primer sequences were extracted from Frasor et al.;
33 18S from Helguero et al.; 6 ERa and ERb sequences will be provided upon request. The standard curve method was used to determine RNA levels.
Whole-cell extracts and immunoblot
Cells were lysed in 1% NP-40, 50 nM Tris-HCl (pH 7.5), 140 nM NaCl, 2 nM EDTA with protease and phosphatase inhibitors, placed 20 min on ice and centrifuged at 14 000 g, 20 min, 4
1 C. In all, 50 mg total proteins were resolved by 7.5 or 10% SDS-PAGE and transferred onto a PVDF membrane. Luminescence was detected with ECL plus (Amersham, Buckinghamshire, UK). Experiments were repeated at least three times in each cell line. Band intensity was quantified with Quantity One software (BioRad) and normalized to loading control (tubulin) intensity. Normalized values were then divided by the untreated control value. Data is presented in graph bars showing relative intensity variation (to the control ¼ 1).
Immunoprecipitation
Cells were lysed in 50 mM Tris-HCl (pH 8), 5 mM EDTA, 150 mM NaCl, 1% triton X-100, 10% glycerol with protease and phosphatase inhibitors. One microgram total protein was incubated with 2 mg anti-ERb 14C8 antibody 50 prebound to magnetic beads overnight at 4 1C. Then, bead-antibody complexes were washed thoroughly with 0.1% tween-20/PBS and resuspended in Laemmli´s buffer for subsequent immunoblot detection.
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